ORAL PROLøFERATøF VERRÜKÖZ LÖKOPLAZø: BøR VAKA RAPORU

Oral verrüköz lezyonlar, genellikle yavaş ilerleyen, gri veya beyaz renkte, yanak mukozası ve dişetinde siğil şeklinde ekzofitik büyümelerdir. Verrüköz karsinoma VK , verrüköz hiperplazi VH , proliferatif verrüköz lökoplaki PVL veya invaziv skuamöz hücreli karsinom SHK şeklinde görülebilirler. Çalışmamızda, PVL tanisi konulan bir vaka raporunu sunmaktayiz. PVL ilk defa Hansen ve ark tarafindan aciklanmis bir lezyondur, hiperkeratotik hastalÕ÷Õn devamÕ olarak gözlenir. Az rastlanÕlan, multi-fokal, yüksek malign transformasyon potansiyeli olan oral lökoplaki çeúididir. Lezyon, avantajlarÕ nedeniyle diyot lazer kullanÕlarak tedavi edildi. Bu avantajlardan birkaçÕ úöyle sÕralanabilir: azalmiú enfeksiyon riski, ödem ve post-operatif a÷rÕ, malign transformasyon riskinin azalmasÕ, daha az invaziv bir yaklaúÕm olmasÕ gibi. PVL tanÕsÕ ile tedavi edilen hastalar malign transformasyon OSHK riski bulundu÷u için 6 ayda bir rutin kontrollere ça÷ÕrÕlmalÕdÕr

Proliferative verrucous leukoplakia PVL : A case report

Oral verrucous lesions, typically presenting as slowly enlarging, grey or white, warty, exophytic overgrowths on the buccal mucosa or gingiva may be verrucous carcinoma VC , verrucous hyperplasia VH , proliferative verrucous leukoplakia PVL , or may show the conventional invasive pattern of squamous cell carcinoma SCC . In our study we reported a case of PVL which is first described by Hansen et al in 1985. PVL is described as a continuum of hyperkeratotic disease, and is an unusual , multi-fokal, progressive form of oral leukoplakia with high malignant potential as well as mortality rates. We treated the patient with diode laser therapy because of its advantages i.e. reduced enfection risk, edema and post operative analgesia effect and elimination of tumor malformation tendency and less invasive approach versus conventional surgery techniques . Given the high tendency for oral squamous cell carcinomas OSCC to appear in these patients, they should be checked for life at least once every 6 months

___

  • )Hansen LS, Olson JA, Silverman S. Proliferative verrucous leukoplakia. A long- term study of thirty patients. Oral Surg Oral Med Oral Path 1985; 60: 285- 98.
  • ) Eversole LR. Papillary lesions of the oral cavity : relationship to human papilloma- viruses. J Calif Dent Assoc 2000: 28(12): 922- 7.
  • ) Gopalakrishnan R, Weghorst CM, Lehman TA, Calvert RJ, Bijur G, Sabourin CL, et al. Mutated and wild-type p53 expres- sion and HPV integration in proliferative ver- rucous leukoplakia and oral squamoz cell car- cinoma. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 1997;83(4):471-7.
  • ) Palefsky JM, Silverman S, Abdel- Salaam M, Daniels TE, Greenspan JS. Asso- ciation between proliferative verrucous leukop- lakia and infection between proliferative ver- rucous leukoplakia and infection with human papillomavirus type 16. J Oral Pathol Med 1995; 24(5):193-7.
  • ) Fettig A, Pogrel MA, Silverman S, Bramanti TE, Da Costa M, Regezi J. Prolifera- tive verrucous leukoplakia of the gingiva. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2000;90(6):723-30.
  • ) Silverman Jr S, Gorsky M. Proliferative verrucous leukoplakia: a follow-up study of 54 cases. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 1997; 84(2): 154-7.
  • ) Gurbuz Oya. Oral Mukozanın Kanser Öncüsü Lezyonları. Turkderm 2012; 46(2): 86- 9.
  • )Radhakrishnan R: Inherited proli- ferative oral disorder:A reductionist approach- to proliferative verrucous leukoplakia. Indian J Dent Res 2011;22:365-6.
  • ) Ge L, Wu Y, Wu L,et al. Case report of rapidly progressive proliferative verrucous le- ukoplakia and a proposal for aetiology in ma- inland China. World J Surg Oncol. 2011; 9:26.